Blueprint Medicines

NASDAQ:BPMCBiotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

2 drugs in development

Phase 21

Preclinical1

By Therapeutic Area

top 3

Ophthalmology

133%

Dermatology

133%

Oncology

133%

R&D Momentum

43/100

Pipeline Velocity

15/100

Trial Completion Rate

71/100

Pipeline Concentration

33/100

Pipeline Freshness

73/100

Strategic Signals

↗Active in Ophthalmology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 26, 2026TrialA Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis

Jun 26, 2026TrialA Multicenter Screening Study to Characterize the Prevalence of the KIT D816V Mutation in Patients With Suspected Clonal Mast Cell Disease

Mar 6, 2026TrialINTRIGUE Extension: Ripretinib vs Sunitinib in GIST

Feb 20, 2026TrialNAVIGATOR: Avapritinib in Indolent SM

Feb 3, 2026TrialA Study of Elenestinib in Healthy Adult Female Participants

Dec 9, 2025TrialA Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

May 28, 2025TrialStudy of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Apr 14, 2025TrialStudy of BLU-808 in Allergic Rhinoconjunctivitis

4 more events

Mar 20, 2025TrialINVICTUS: Ripretinib in Fourth-Line GIST

Nov 28, 2024TrialAvapritinib Rollover Study

Aug 7, 2024TrialStudy of BLU-808 in Healthy Adult Participants

Sep 25, 2023TrialStudy of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Founded2008

ExchangeNASDAQ:BPMC

Therapeutic Focus

OncologyOphthalmologyDermatology

Patent Expirations

3 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Ayvakit4 patentsOct 15, 2034 Ayvakit3 patentsApr 10, 2040 AyvakitMar 8, 2042

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Regulatory

Regulatory Timeline

20211 event

FDAJun 16

Ayvakit — AYVAKIT

Application NDA212608 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)